Overview
Preclinical evaluation of a vitamin D analog for the treatment of vitamin D 24-hydroxylase using fibroblast from patients with CYP24A1 mutation.
Eligibility
Inclusion Criteria:
- biallelic mutation in CYP24A1
- consent
Exclusion Criteria:
- none
Preclinical evaluation of a vitamin D analog for the treatment of vitamin D 24-hydroxylase using fibroblast from patients with CYP24A1 mutation.
Inclusion Criteria:
Exclusion Criteria:
NCT04987073
University Hospital, Caen
4 August 2025
Congrats! You have your own personal workspace now.